COVID-19 Vaccine Provider Weekly Updates

Stay Safe MN logo

COVID-19 Vaccine Provider Weekly Updates

View this as a webpage

Minnesota Department of Health

April 7, 2022


Coming soon: Anticipated Moderna COVID-19 vaccine booster only vials

Moderna is currently making a blue cap multi-dose vial that will only be used for booster doses. It will contain five booster doses of 0.5ml, 50 µg dose. This formulation cannot be used for completion of the primary series and is only to be used for booster dose administration. The emergency use authorization (EUA) FDA: Moderna COVID-19 Vaccine Fact Sheets were updated last week for this product .

We anticipate that this product will be available in the coming weeks. MDH is carefully considering how this packaging will be added to ordering given the potential for medical errors. Look for further information in coming bulletins.

The original Moderna COVID-19 vaccine can be used for either primary or booster doses and will continue to be available.

Table 1. COVID-19 vaccine formulations currently approved or authorized in the United States

Columns include age indicated, cap color and dosage.Rows list dosages by cap color. Full table in the following link.

CDC: Clinical Guidance for COVID-19 Vaccination

At this time Moderna blue cap will not be included in the vaccine ordering event in MIIC while MDH assesses demand for the product. For further details regarding Modera blue cap refer to: CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines or FDA: Fact Sheet for Vaccination Providers EUA of Moderna.

. The product appears as Spikevax-MOD 50mcg DKB in the MIIC user interface. The MIIC code sets have also been updated to include the CVX, CPT, and MVX codes for this product. For more information on MIIC codes sets refer to MIIC Codes for Data Submission and Exchange or Entering COVID-19 Product Information in MIIC.

Exhaustion of federal funding for uninsured program and coverage assistance fund

Due to the lack of supplemental funding from Congress, the Health Resources and Services Administration (HRSA) stopped accepting claims for reimbursement of costs associated with administering COVID-19 vaccines to uninsured patients as of April 5. Refer to the COVID-19 Vaccine Provider Weekly Update on March 30, 2022 for additional details.

As outlined in your provider enrollment agreement, participating providers must continue to administer COVID-19 vaccine at no cost to all patients to ensure equitable access for all people. CDC clarified this week that enrolled providers are prohibited from doing the following specific actions:

  • Administering COVID-19 vaccine at any out-of-pocket cost to the recipient.
  • Denying anyone vaccination, or differentially reducing appointment access, based on the vaccine recipient’s coverage status or network status.
  • Charging an office visit or other fee if COVID-19 vaccination is the sole medical service provided.
  • Requiring additional medical services to receive COVID-19 vaccination.
  • Seeking any reimbursement, including through balance billing, from the vaccine recipient.

For more information please visit: CDC: Requirements for COVID-19 Vaccination Program Providers.

Option to opt out of adult ancillary kits

Starting April 11 you will have the option to opt out of all adult vaccine ancillary supply kits, including the Pfizer adult ancillary kits. If you would like to opt out, make a note in the Special Delivery Instructions field when ordering in MIIC. The opt out option is not currently available for pediatric COVID-19 vaccine as Pfizer pediatric ancillary kits contain the diluent necessary to administer the vaccine.

Find previous bulletins at COVID-19 Vaccine Provider Updates.